arrow_back Back to App

Safer Medications: Better Dosing and Fewer Side Effects

This act aims to reduce adverse drug reactions through education, improved medical systems, and research. Citizens can expect safer treatment, better tailored to their individual genetic needs, reducing the risk of complications and hospital visits.
Key points
Public Education: Increasing awareness about drug risks and the benefits of pharmacogenomic testing, which helps select appropriate medications and dosages.
Improved Medical Systems: Changes to electronic health records to give doctors easier access to patient genetic information, helping avoid dangerous drug interactions.
Support for Healthcare Providers: Educational programs for healthcare professionals to better understand and utilize pharmacogenomic testing in treatment.
Reduced Side Effects: Initiatives to lower the number of adverse reactions to common medications like anticoagulants, hypoglycemic agents, and opioid analgesics.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_6875
Sponsor: Rep. Swalwell, Eric [D-CA-15]
Process start date: 2022-02-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Right Drug Dose Now Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_6875.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-02-28.

What are the main provisions?

Key points include:

  • Public Education: Increasing awareness about drug risks and the benefits of pharmacogenomic testing, which helps select appropriate medications and dosages.
  • Improved Medical Systems: Changes to electronic health records to give doctors easier access to patient genetic information, helping avoid dangerous drug interactions.
  • Support for Healthcare Providers: Educational programs for healthcare professionals to better understand and utilize pharmacogenomic testing in treatment.
  • Reduced Side Effects: Initiatives to lower the number of adverse reactions to common medications like anticoagulants, hypoglycemic agents, and opioid analgesics.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Swalwell, Eric [D-CA-15].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health